Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Coviccine Trivalent XBB
- Development stage
- Phase 3
- Lead developer
- WestVac Biopharma
- Modality
- Recombinant Proteins and Enzymes, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**Coviccine Trivalent XBB (WSK-V102C)** is a recombinant protein vaccine developed by WestVac BioPharma using an Sf9 insect cell platform. It targets SARS-CoV-2 by incorporating receptor-binding domains (RBDs) from XBB.1.5, BA.5, and Delta variants fused to the spike protein's heptad repeat (HR) domain, forming stable trimeric particles adjuvanted with a squalene-based oil-in-water emulsion. Primarily indicated as a booster for COVID-19 prevention in adults aged 18+, it elicits broad neutralizing antibodies against diverse Omicron sublineages including XBB descendants, JN.1, and BA.2.87.1, with demonstrated 93.28% protective efficacy against XBB.1, XBB.1.5, and XBB.1.9, and an excellent safety profile.[2][3][4]
- Brand names
- Coviccine Trivalent XBB
- Other names
- Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)Trivalent recombinant protein COVID-19 vaccine - WestVac BiopharmaCoviccine® Trivalent XBB Vaccine (WSK-V102C)
02
Targets
RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on Coviccine Trivalent XBB.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Coviccine Trivalent XBB.